PLoS ONE (Jan 2018)

The prevalence of endoscopic gastric mucosal damage in patients with rheumatoid arthritis.

  • Saki Tsujimoto,
  • Sho Mokuda,
  • Kenichiro Matoba,
  • Akihiro Yamada,
  • Kazuo Jouyama,
  • Yosuke Murata,
  • Yoshio Ozaki,
  • Tomoki Ito,
  • Shosaku Nomura,
  • Yasuaki Okuda

DOI
https://doi.org/10.1371/journal.pone.0200023
Journal volume & issue
Vol. 13, no. 7
p. e0200023

Abstract

Read online

OBJECTIVES:Rheumatoid arthritis (RA) patients often take non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids as supportive drugs. In this study, we investigated the prevalence of endoscopic gastric damage and their prescribed medications under an actual clinical condition. METHODS:We collected the data of 1704 RA patients who underwent upper gastrointestinal fiberscopy. Gastric mucosal erosion and ulcer were classified using modified LANZA score. We analyzed these data with a multiple regression analysis. RESULTS:The prevalence of endoscopic gastric mucosal damage in these RA patients was 16.7% (285 cases). A multiple regression analysis indicated that prednisolone (PSL), NSAIDs and proton pump inhibitors (PPIs) were independent risk factors associated with the modified LANZA score. PSL and NSAIDs were positively correlated with the score, while the administration of PPIs was inversely correlated with the score. The modified LANZA score in RA patients treated with both PSL and NSAIDs was significantly higher than that in those treated with PSL alone (no NSAIDs use). CONCLUSIONS:Our findings suggest that PSL and NSAIDs were exacerbating factors for gastric mucosal damage, while PPIs usage was a protective factor. And, the combined usage of corticosteroids and NSAIDs may induce the development of gastric ulcers.